Dupuytren’s Disease (Palmar Fibromatosis) Market Outlook

Thelansis’s “Dupuytren’s Disease (Palmar Fibromatosis) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dupuytren’s Disease (Palmar Fibromatosis) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dupuytren’s Disease (Palmar Fibromatosis) Overview

Dupuytren’s disease, also known as Palmar fibromatosis, is characterized by the gradual thickening and contraction of the palmar fascia, a layer of tissue beneath the skin and above the tendons, nerves, blood vessels, and bones in the palm and fingers. This fibrous layer stabilizes the skin on the palm side of the hand, preventing excessive mobility. However, in individuals with Dupuytren’s, the fascia thickens over time, resulting in a tightening or shortening effect. Typically, the initial indication of Dupuytren’s is the formation of nodules, or lumps of tissue, beneath the skin in the palm. As the condition progresses slowly over the years, these nodules may evolve into cords, leading to contractures. Signs and symptoms of Dupuytren’s include nodules, cords, and contractures. Dupuytren’s disease is not life-threatening and does not metastasize to vital organs. A benign proliferation of myofibroblasts and fibroblasts characterizes it. While the exact cause remains unclear, several factors, such as repetitive trauma, smoking, alcohol addiction, frozen shoulder, epilepsy, and long-term phenobarbital usage, have been associated with its development.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)